HAEi News

Life-saving medication to South African HAE patients

2019-07-16T13:31:49+02:00July 8, 2019|HAEi News|

A ‘one-of-a-kind’ medication access program from HAE International is now successfully delivering potentially life-saving medication to HAE-patients in South Africa. “As no modern medications have been commercially available in South Africa until now, HAE patients have been unable to access them. The HAE International Global Access Program offers a regulatory compliant process that allows [...]

“Global Perspectives” #2/2019 out now

2019-07-08T08:40:09+02:00July 6, 2019|HAEi News, Newsletters|

Dear HAE friends, Welcome to the second 2019 issue of the HAEi magazine Global Perspectives. This time you will, among many other items, find information on: News from the HAEi Regional Patient Advocates Life-saving medication to South African HAE patients Another success on the road to Santiago 11th C1-INH Deficiency & Angioedema Workshop including summaries [...]

New record in raising awareness step by step

2019-07-09T12:56:52+02:00June 7, 2019|HAEi News|

HAE International extends a very warm thank you to each and everyone who took part in the HAE Global Walk from 1 April to 31 May 2019 – once more proving that this is a truly worldwide HAE event. “First launched in 2016 the HAE Global Walk registered more than 12,000,000 steps. In 2017 the [...]

Prevention of HAE attacks during early treatment phase

2019-07-06T22:18:06+02:00June 4, 2019|HAEi News|

Takeda Pharmaceutical Company Limited presents new data from an ad-hoc analysis of the Phase 3 HELP Study™, designed to evaluate the onset of action for TAKHZYRO (lanadelumab) during days 0-69 of treatment. The analysis suggests that TAKHZYRO starts to prevent HAE attacks during this early treatment phase, with patients experiencing an 80.1% decrease in mean [...]

Rapid suppression of plasma kallikrein activity

2019-07-06T22:18:30+02:00May 28, 2019|HAEi News|

At the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary earlier this month KalVista Pharmaceuticals, Inc. presented new data regarding its KVD900 project. “KVD900 is an oral, novel, potent and selective inhibitor of plasma kallikrein, a validated target in HAE,” said Andrew Crockett, CEO of KalVista. “We believe KVD900 represents a new therapeutic opportunity [...]

Phase 3 trial meets primary endpoint

2019-06-04T15:21:14+02:00May 21, 2019|HAEi News|

The randomized (n=121), double-blind, placebo-controlled, Phase 3 APeX-2 trial of once-daily, oral BCX7353 for the prevention of HAE attacks has achieved its primary endpoint for both dose levels (110 mg and 150 mg), with the 150 mg dose reducing the attack rate in HAE patients by 44 percent (p<0.001) compared to placebo. Fifty percent of [...]

Turning an HAE Walk Into a Pilgrimage

2019-07-09T12:58:00+02:00May 16, 2019|HAEi News|

Many of us show support by doing a charity walk or running a 5K - events that usually take the better part of a morning. But is there a cause that you would walk three days for? For 50 people who will gather in Spain this week, the answer is yes and the cause is [...]

Pharming celebrates hae day :-)

2019-07-09T12:59:02+02:00May 16, 2019|HAEi News|

On 16 May each year, HAE patient organisations from around the world, led by the HAEi, the international umbrella organisation for the world’s HAE patient groups, come together to support awareness of HAE. hae day :-) aims to raise global awareness to ensure each and every patient receives faster diagnosis and the care they need [...]

HAEi Global Access Program provides life-saving medication to South African HAE patients

2019-05-22T10:13:47+02:00May 16, 2019|HAEi News|

A ‘one-of-a-kind’ medication access program from HAE International (HAEi) is now successfully delivering potentially life-saving medication to patients in South Africa, who suffer from the rare genetic condition hereditary angioedema (HAE).HAE causes severe and unpredictable swelling (edema) in different areas of the body including the hands, feet, and face. Patients experience bouts of excruciating abdominal [...]

BioCryst reports significant progress

2019-05-15T11:32:31+02:00May 8, 2019|HAEi News|

“In a year with many milestones across our multiple advancing programs of oral medicines for rare diseases, BioCryst Pharmaceuticals, Inc. has achieved significant progress in the first quarter and we look forward to reporting data from our APeX-2 trial in the second quarter and filing a new drug application by the end of the year,” [...]